Caribou Biosciences

Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

-- Tim Kelly to lead Caribou's technical operations strategy and execution -- -- CB-010 ANTLER Phase 1 trial initial dose expansion data and RP2D to be disclosed Q2 2024; Caribou plans to initiate pivotal Phase 3 trial in 2L LBCL by YE 2024 --

Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024

CRISPR Therapeutics

Intellia Therapeutics

Gene editing stocks have received a lot of attention throughout 2023. The intense focus on gene editing therapies and CRISPR technology is likely only to increase moving forward: The U.S. Food and Drug Administration (FDA) just approved the world's first medicine employing CRISPR technology.

3 Gene-Editing Stocks With the Potential to Mint Millionaires

-- Caribou met with the FDA and reached alignment on a pivotal trial in 2L LBCL with CB-010 versus a comparator arm of immunochemotherapy followed by HDCT and ASCT -- -- ANTLER Phase 1 trial continues dose expansion enrollment; initial dose expansion data and RP2D expected Q2 2024 --

Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024

Caribou Biosciences, Inc. (CRBU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Caribou Biosciences, Inc. (CRBU) Upgraded to Buy: What Does It Mean for the Stock?

Gilead Sciences

Using gene therapy, companies can change patients' DNA. One type of gene therapy, called CRISPR, largely mimics a method used by bacteria to fend off viruses.

Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy

The mean of analysts' price targets for Caribou Biosciences, Inc. (CRBU) points to a 285.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Caribou Biosciences, Inc. (CRBU) Could Rally 285.29%: Here's is How to Trade

ARK Genomic Revolution Multi-Sector ETF

Beam Therapeutics

Editas Medicine

Robinhood

Eli Lilly

Prime Medicine Inc

Regeneron Pharmaceuticals

Verve Therapeutics

Vertex Pharmaceuticals

Genomic medicine is predicted to become a multi-billion-dollar industry. Even so, this market will probably take years to mature, and risks abound as a result.

You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.

In July, Caribou Biosciences reported positive data from the Antler study of its CAR-T therapy, CB-010, and a $25M investment from PFE. Data from the dose expansion portion of the Antler study are expected in H1'24, but given previous conservative guidance for timelines from CRBU, might come in Q1'24. The Company has $396.7M in cash, which it expects to fund operations into Q4'25.

Caribou Biosciences: Upcoming CB-010 Data Could Send The Bears Packing

The average of price targets set by Wall Street analysts indicates a potential upside of 321.5% in Caribou Biosciences, Inc. (CRBU). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Caribou Biosciences, Inc. (CRBU) Have the Potential to Rally 321.46% as Wall Street Analysts Expect?

-- CB-010 ANTLER Phase 1 trial continues enrolling second-line r/r LBCL patients in dose expansion; plan to share FDA feedback by year-end 2023 and report initial dose expansion data in H1 2024 -- -- CB-011 CaMMouflage Phase 1 trial enrollment ongoing in r/r MM patients --

Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update

-- Dr. Jagannath is a renowned expert in the research and treatment of multiple myeloma -- BERKELEY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) --  Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Sundar Jagannath, MD, to its scientific advisory board. With four decades of experience, Dr. Jagannath is a renowned expert in bone marrow transplantation and treating patients with multiple myeloma, and he is the director of the Center of Excellence for Multiple Myeloma at The Tisch Cancer Institute and professor of medicine, hematology and medical oncology, at Mount Sinai School of Medicine, New York.

Caribou Biosciences Announces Appointment of Sundar Jagannath, MD, to its Scientific Advisory Board

Chewy

Chewy has reached the big milestone of profitability and is expanding -- without a huge investment -- internationally. Caribou is progressing with a cutting-edge gene-editing technique that could lead to major growth down the road.

2 Top Growth Stocks to Buy Right Now Without Hesitation

-- AMpLify Phase 1 clinical trial to initiate patient enrollment by mid-2024 -- -- CB-012 is the first allogeneic CAR-T cell therapy with both checkpoint disruption and immune cloaking to enter the clinic --

Caribou Biosciences Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Ginkgo Bioworks Holdings

Caribou's gene editing technology has delivered positive results so far in its early-stage clinical trials. Ginkgo Bioworks may help top pharma companies make better drugs.

2 Exciting Biotech Stocks to Buy With Less Than $10

Caribou Biosciences stock could rocket up more than 400%, according to the consensus price target from Wall Street analysts. Caribou's lead candidate is an off-the-shelf cellular cancer therapy for lymphoma patients.

A Bull Market Is Coming: 1 Beaten-Down Growth Stock You Could Regret Not Buying on the Dip

Growth stocks have rebounded to a degree this year. Even so, developmental biotech companies have still had a rough year as a whole in 2023.

2 Magnificent Growth Stocks to Buy On the Dip

BERKELEY, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Reigin Zawadzki to the newly created position of chief people officer. Ms. Zawadzki brings over 20 years of experience leading human resources in the biotechnology industry. She will lead Caribou's people strategy and report to Rachel Haurwitz, PhD, president and chief executive officer.

Caribou Biosciences Appoints Reigin Zawadzki as Chief People Officer

Caribou Biosciences has plenty of money for the next year or so, and great data. Editas Medicine is far behind the competition with its lead programs.

1 Gene Editing Stock to Buy Now, and 1 to Sell

Recursion Pharmaceuticals

Biotechs tend to be very risky investments. Picking businesses with good management and plenty of cash can reduce risk.

3 Clever Tricks to Find Winning Biotech Stocks

Here is how Caribou Biosciences, Inc. (CRBU) and DexCom (DXCM) have performed compared to their sector so far this year.

Is Caribou Biosciences (CRBU) Stock Outpacing Its Medical Peers This Year?

-- CB-010 ANTLER trial dose expansion enrolling second-line LBCL patients; plan to share FDA feedback by YE 2023 and report initial dose expansion data in H1 2024 -- -- CB-011 CaMMouflage Phase 1 trial enrollment continues in r/r MM --

Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update

Caribou's cell therapy programs are among the most advanced that exist. So far, they also appear to be relatively safe and quite effective.

3 Reasons Why Caribou Biosciences Is a Screaming Buy in July and Beyond

It's cumbersome and costly to manufacture complicated cell therapies. Caribou Biosciences and CRISPR Therapeutics have a better way of doing things.

This 1 Innovation Could Make These 2 Biotechs Soar by 2030

Caribou Biosciences just released promising data on its lead cancer therapy. It also just issued a bunch of new stock, improving its cash position.

Got $1,000? Buying Caribou Biosciences Stock Right Now Could Be a Brilliant Move in 5 Years

Alignment Healthcare

The market has already risen sharply this year, but Wall Street analysts think these two stocks haven't received the attention they deserve. Caribou Biosciences is a clinical-stage drugmaker developing one-size-fits-all cellular cancer therapies.

News for Caribou Biosciences Stock (CRBU)